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Programmed Hydrolysis in 
Designing Paclitaxel Prodrug for 
Nanocarrier Assembly
Q. Fu1, Y. Wang1, Y. Ma4, D. Zhang1, J. K. Fallon3, X. Yang1, D. Liu2, Z. He1 & F. Liu3,ς
Nanocarriers delivering prodrugs are a way of improving in vivo effectiveness and efficiency. For 
therapeutic efficacy, the prodrug must hydrolyze to its parent drug after administration. Based on 
the fact that the hydrolysis is impeded by steric hindrance and improved by sufficient polarity, in this 
study, we proposed the PTX-S-S-VE, the conjugation of paclitaxel (PTX) to vitamin E (VE) through a 
disulfide bridge. This conjugate possessed the following advantages: first, it can be encapsulated in 
the VE/VE2-PEG2000/water nanoemulsions because of favorable hydrophobic interactions; second, the 
nanoemulsions had a long blood circulation time; finally, the concentrated glutathione in the tumor 
microenvironment could cleave the disulfide bond to weaken the steric hindrance and increase the 
polarity, promoting the hydrolysis to PTX and increasing the anticancer activity. It was demonstrated 
in vitro that the hydrolysis of PTX-S-S-VE was enhanced and the cytotoxicity was increased. In 
addition, PTX-S-S-VE had greater anticancer activity against the KB-3-1 cell line tumor xenograft 
and the tumor size was smaller after the 4th injection. The present result suggests a new way, use 
of reduction, to improve the in vivo anticancer activity of a prodrug for nanocarrier delivery by 
unshielding the ester bond and taking off the steric block.
A prodrug improves the properties of a parent drug by linking with or being modified by a functioning 
or non-functioning molecular group1,2. Prodrug strategy has been used to improve aqueous solubility, 
enhance chemical stability, promote transport across epithelial cells, reduce pre-systemic metabolism, 
and increase oral absorption3–6. It is administered in an inactive form, and it must convert or hydrolyze 
to its active form through physiological metabolism7,8. As estimated, prodrugs accounted for about 17.8% 
(34 of the 191) of new chemical entities approved between 2000 and 2008, and prodrug prevalence was 
15.4% among the top 100 bestselling small molecular weight drugs in 20089,10.
Paclitaxel (PTX) is widely used for the treatment of non-small cell lung cancer, breast cancer, ovarian 
cancer and AIDS-related Kaposi’s sarcoma11. Both Taxol®12,13 and Abraxane® 14,15 are commercial PTX 
formulations approved by the FDA. However, due to their low drug loadings and the problems associated 
with the burst release, experts have applied a prodrug strategy to improve the in vivo performance of 
PTX16,17. Some researchers have conjugated PTX with a hydrophilic polymer18–23, but the drug loading 
was still very low. In addition, the half-lives of the formulations are too short, leading to poor efficacy 
in vivo, although this strategy has prolonged the release and exhibited promising anticancer activity in 
vitro. Others have conjugated PTX with a hydrophobic chain24–27, in the hope that it could improve the 
compatibility between cargo and carrier, facilitating encapsulation in a nanocarrier. Nevertheless, the 
potential anticancer activity was limited due to poor hydrolysis, as evidenced by the fact that no more 
than 10% of PTX-linoleic acid conjugate was hydrolyzed to PTX at 48 h28.
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In our group, PTX-VE (Fig. 1) has been synthesized by conjugating PTX and vitamin E (VE) together 
via an ester bond, and it has been encapsulated in the VE/VE2-PEG2000/water nanoemulsions (NES) 
because PTX-VE, VE, and VE2-PEG2000 were molecularly matched. Based on this, we have codelivered 
PTX and 5-fluoroucacil in a same nanoparticle by their conjugation with the VE29. What is more, using 
the same strategy, theranostic (PTX, and sulforhodamine B) has been also achieved30. However, PTX-VE 
did not release active PTX in vitro within 48 h, resulted in negotiated cytotoxicity. Thus, the aim of 
this paper was to find out a substitute for PTX-VE. We initially demonstrated that its hydrolysis was 
impeded by steric hindrance and improved by sufficient polarity, by grafting different groups onto PTX. 
Then, we proposed and synthesized PTX-S-S-VE, PTX conjugated with VE via a disulfide bond, a redox 
sensitive bridge (Fig. 2). This bridge would be broken in tumor cells because of the sufficient glutathione 
(GSH) concentration (2–8 mM)31, to promote the hydrolysis. In addition, the PTX-S-S-VE can also be 
encapsulated and assembled as PTX-S-S-VE/VE/VE2-PEG2000/water NES for administration because of 
favourable hydrophobic interactions between the prodrug and the nanocarrier. The tissue distribution, 
in vivo antitumor activity and hemolytic activity were evaluated for PTX-S-S-VE/VE/VE2-PEG2000/water 
NES, with PTX-VE/VE/VE2-PEG2000/water NES and Taxol® as reference formulations.
Results and discussion
Proof-of-concept. In the hydrolysis study, the PTX-VE was not hydrolyzed until 48 h. The reason for 
the poor hydrolysis of PTX-VE might be that the hydrolytic site (C-2' hydroxyl group in PTX) is steri-
cally shielded by the VE. To test this hypothesis, PTX-SEE (the VE group substituted by a methyl group) 
was synthesized. Both PTX-VE and PTX-SEE are hydrophobic. As shown in Fig.  3a, approximately 
20.7% of PTX-SEE was hydrolyzed to free PTX by 48 h, a much higher percentage than for PTX-VE. 
This indicates that steric hindrance could be a major reason for impeded hydrolysis.
In addition to this, Markovic et al. established a good correlation (R = 0.9924) between solvolytic 
rate constants and polarity, indicating enhanced polarity could improve hydration for a prodrug32. It 
Figure 1. Chemical structures of PTX, PTX-VE, PTX-SEE, PTX-SA, and PTX-S-S-VE. 
Figure 2. Schematic illustration for the enhanced hydrolysis of PTX-S-S-VE. The prodrug will experience 
a two stepped hydrolysis to overcome the steric hindrance and polarity hurdles. The disulfide bond will 
be cleaved in tumor cells because the concentration of GSH in tumor cells is much higher than in blood 
plasma. This initial hydrolysate will then be further hydrolyzed to PTX because of the increased polarity.
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is reasonable to assume that the hydrolysis rate is dependent on polarity to some extent. Therefore, we 
conjugated PTX and succinic acid directly to produce PTX-SA. In comparison with PTX-SEE, PTX-SA 
had increased polarity, which was evidenced by the retention time (6.7 min for PTX-SA and 31.7 min 
for PTX-SEE) in a reversed phase chromatography system (Figure S6). As expected, PTX-SA had a 
higher hydrolytic profile than PTX-SEE, suggesting that sufficient polarity might be the other reason for 
hydrolysis.
Therefore, decreased steric hindrance and enhanced polarity favor increased hydrolysis.
Cytotoxicity demonstration. For PTX, the hydroxyl group at the C-2' position is important for its 
anticancer activity and it must therefore be exposed to the external environment to have its effect16,17. 
Thus, the hydrolytic rate for a PTX prodrug may therefore influence its in vitro cytotoxicity. In this 
research, the cytotoxicity was investigated on the KB-3-1 cell line using the MTS method. Free PTX, 
PTX-SA, PTX-SEE, and PTX-VE were added to the cells, respectively, with concentrations ranging from 
0.1–0.5 μ M. As shown in Fig. 3b, PTX-VE had no inhibitory effect when concentration was up to 0.5 μ M 
because of the negligible hydrolysis, and its IC50 value was as high as 2.67 μ M. For PTX-SEE, the inhi-
bition effect was greater, and the viability was about 72.8% when cells treated with 0.5 μ M of PTX-SEE. 
In the case of PTX-SA, the IC50 was 0.252 μ M. In addition, free PTX had the strongest inhibition effect. 
The cytotoxicity did correlated well with the hydrolytic rate.
Rational design for PTX-S-S-VE. In a previous study, we have developed PTX-VE/VE/VE2-PEG2000/
water NES and demonstrated sufficiently high drug loading and improved pharmacokinetics, because the 
PTX-VE was subjected to strong interactions with the VE and VE2-PEG2000. However, the cytotoxicity 
of PTX-VE was very low because of poor hydrolysis. Therefore, in this study, we would like to develop 
a substitute for PTX-VE, by maintaining the VE group and changing the linker, in order to improve the 
hydrolysis.
On the basis of the analysis above and considering the redox nature of the tumor microenvironment33, 
we undertook to synthesize PTX-S-S-VE (PTX conjugated with VE via a disulfide bond) because the 
sufficient GSH34,35 in tumor cells will cleave the bridge and promote the hydrolysis to free PTX. As shown 
in Fig. 4, the hydrolysis rate was accelerated with GSH concentration increased. In addition, compared 
with PTX-VE, the in vitro hydrolysis was improved and its anticancer activity was increased.
Preparation, characterization and storage stability of the NES. PTX-VE/VE/VE2-PEG2000 
NES has been prepared because of favorable affinity for PTX-VE, VE, and VE2-PEG2000. In this study, 
PTX-S-S-VE/VE/VE2-PEG2000 NES was also prepared successfully. The particle size, zeta potential, and 
morphology were characterized. As shown in Fig. 5, for both NES, the particles were of similar spheri-
cal shape and size (100–150 nm). Consistent with the TEM images, the dynamic light scattering results 
showed that both NES were about 130 nm (Table 1, and Figure S8–9). The small PDI indicated that the 
particles were of a narrow size range. It was demonstrated that the PTX-S-S-VE/VE/VE2-PEG2000 NES 
was physically stable for at least 12 months (Table S1). Therefore, the PTX-S-S-VE/VE/VE2-PEG2000 NES 
was suitable for in vivo studies.
Tissue distribution. To evaluate the in vivo performance, the CD1 mice, in the biodistribution 
study, were administrated intravenously a single dose equivalent of 20 mg/kg PTX. The mice were sac-
rificed at 4 h and the tissues were harvested. The biodistribution of free PTX and PTX prodrugs are 
shown in Fig.  6a,b, respectively. For PTX-VE NES, free PTX was only found in the liver, with only a 
small amount being found in other tissues. This was because of the low cleavage rate of the ester bond, 
Figure 3. Hydrolytic release profiles in pH 7.4 PBS containing 7% DMSO and 0.1% Tween 80 (a) and 
in vitro cytotoxicity against KB-3-1 cell line for PTX-VE, PTX-SEE, and PTX-SA (b). These studies were 
carried out at 37 °C.
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and indicated similar in vivo hydrolytic behavior to that seen in vitro. On the other hand, PTX-VE 
NES showed high prodrug accumulation, including higher than that of PTX-S-S-VE NES, with liver 
(3794.0 ± 1241.6 ng/g) being the major distribution tissue followed by spleen (1753.1 ± 666.7 ng/g) 
and then kidney (1351.4 ± 179.3 ng/g). The reason for this could be attributed to matching properties 
of VE oil and the VE group in PTX-VE, as well as PTX-VE being less susceptible to hydrolysis than 
PTX-S-S-VE. Importantly, it exhibited comparable prodrug distribution in tumors for PTX-VE NES and 
Figure 4. In vitro hydrolytic profiles and cytotoxicity against KB-3-1 cell line for PTX-S-S-VE (data are 
expressed as the mean ± SD, n = 5 wells for each formulation at each concentration). These studies were 
carried out at 37 °C.








PTX-VE NES 134.6 ± 0.6 0.175 ± 0.012 –4.03 ± 0.27
PTX-S-S-VE NES 128.1 ± 0.4 0.164 ± 0.027 –3.99 ± 0.26
Table 1.  Particle sizes and zeta-potentials of PTX-VE/VE and PTX-S-S-VE/VE NES (data are expressed 
as the mean ± SD, n = 3 for each measurement).
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PTX-S-S-VE NES. In the case of PTX-S-S-VE NES, greater free PTX accumulation was seen than for 
Taxol® in most tissues. The distribution was statistically higher than Taxol® in plasma (p < 0.05), liver 
(p < 0.05), spleen (p < 0.05), kidney (p < 0.05) and tumor (p < 0.05, Student’s t-test, paired, two sided). 
This could be because PTX-S-S-VE and VE are molecularly matched resulting in longer circulation of the 
PTX-S-S-VE NES in the blood and hence longer in vivo retention time than for the Taxol®. In addition, 
the GSH in blood, despite being of much lower concentration than in the tumor, could start the hydro-
lytic program to some extent, leading to enhanced hydrolysis. The in vivo distribution results indirectly 
reflect the hydrolytic properties of the prodrugs.
Tumor growth inhibition. To evaluate the in vivo therapeutic effect of the formulations, tumor 
growth inhibition was studied in a KB-3-1 cells subcutaneous model in Balb/C nude mice. As shown 
in Fig. 7, the control group showed very rapid tumor growth. There was no significant reduction of the 
tumor volume in mice treated with PTX-VE/VE/VE2-PEG2000 NES (p > 0.05, Student’s t-test, paired, two 
sided). However, the mean tumor volume was slightly smaller than for the controls. Not surprisingly, the 
greatest antitumor activity was observed when the mice were treated with PTX-S-S-VE/VE/VE2-PEG2000 
NES. For this formulation, the tumors were diminished before the fifth injection. Similarly, Taxol® also 
showed a strong tumor inhibition effect and only one mouse was found to still bear the tumor by the 
15th day. In addition, no weight loss occurred in all groups (Fig. S10).
In vivo toxicity 
Histopathological examination. In order to determine if the accumulation of the formulations is able to 
damage normal tissues, the histopathological of the heart, liver, spleen, lung, and kidney for each treat-
ment group was examined. The results were shown in Fig. S11. Lesions were not found in the PTX-VE/
VE and PTX-S-S-VE/VE NES treated group. However, it is clear that the kidney, in Taxol® treated group, 
suffers from dilatation and congestion for renal interstitial vascular.
Figure 6. Tissue distribution of parent drug (a) and prodrugs (b) at 4 h after intravenous administration 
of Taxol® , PTX-VE/VE/VE2-PEG2000/water and water NES PTX-S-S-VE/VE/VE2-PEG2000/ at a PTX 
equivalent single dose of 20 mg/kg at 4 h (p < 0.05 [*] and p < 0.01 [**]).
Figure 7. Inhibition of tumor growth by Taxol®, PTX-VE/VE/VE2-PEG2000/water and PTX-S-
S-VE/VE/VE2-PEG2000/water NES in KB-3-1 cell subcutaneous xenografts. The formulations were 
administered intravenously at an equivalent dose of 5 mg/kg of PTX every second day for 5 injections in 
total (data are expressed as the mean ± SD, n = 5 mice for each formulation) (p < 0.05 [*] and p < 0.01 [**]).
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Measurement of serum level. AST and ALT are two tests usually used to evaluate the main liver func-
tion. In this study, the ALT and AST were significantly elevated in the group treated with Taxol® but not 
with the PTX-S-S-VE/VE/VE2-PEG2000/water NES (Table  2), indicating PTX-S-S-VE/VE/VE2-PEG2000 
NES is much better tolerated than Taxol®.
Hemolysis study. It is acknowledged that hemolysis is a major drawback for surfactant based formula-
tions, such as Taxol®. In this study, TPGS and VE2-PEG, which can each also cause hemolysis, were used 
for stabilizing the NES. Therefore, to evaluate the safety of the two NES, we studied the hemolysis effect 
by incubating erythrocytes with the formulations (Taxol®, PTX-VE/VE/VE2-PEG2000 NES, PTX-S-S-VE/
VE/VE2-PEG2000 NES, and Abraxane® ) for 1 h at different PTX concentrations. Figure 8 shows hemol-
ysis results for the formulations at various concentrations. At 0.0293 μ M of PTX, all formulations were 
nonhemolytic. As the concentration was increased, hemolysis appeared. At the highest concentration 
tested (0.117 μ M), 91.3% of the erythrocytes were hemolyzed for the Taxol® group, while only 19.5%, 
15.6%, and 12.9% of erythrocytes were hemolyzed for PTX-S-S-VE/VE/VE2-PEG2000 NES, PTX-VE/VE/
VE2-PEG2000 NES, and Abraxane® , respectively. Therefore, it can be suggested that both of the prodrug 
NES formulations are safer than Taxol® in terms of membrane toxicity.
Material and Methods
Materials. PTX was purchased from Lc Laboratories (Woburn, MA). PTX injection (Taxol®) was man-
ufactured by Ben Venue laboratories, Inc. (Bedford, OH). TPGS was purchased from Eastman Chemical 
Company (Anglesey, U.K.). (+ )-a-Tocopherol (VE), D-a-Tocopherol succinate, N, N-dicyclohexylurea 
tert-butyl-2-aminoethylcarbamate, trifluoroacetic acid, tert-butyl methyl ether were purchased from 
Sigma-Aldrich Corporation (St. Louis, MO).
Synthesis of PTX-VE, PTX-SA, PTX-SEE, and PTX-S-S-VE 
Synthesis of PTX-VE. PTX (100.0 mg, 0.117 mmol) was reacted with D-α -tocopherol succinate (62.0 mg, 
0.117 mmol) in the presence of N, N’-dicyclohexylcarbodiimide (48.2 mg, 0.234 mmol) and a catalytic 
amount of dimethylaminopyridine (DMAP) in anhydrous dichloromethane (8 mL) at room temperature 
AST(U/L) ALT(U/L) BUN(mg/dL)
Taxol® 398.6 ± 88.7 140.2 ± 44.5 21.8 ± 2.2
PTX-VE NEs 198.0 ± 35.7* 35.2 ± 6.3* 24.2 ± 1.3
Normal Range 54–298 17–77 8–33
Table 2.  Kidney and liver function parameters (AST, ALT, and BUN) in the different experimental 
group. Values are expressed as mean ± SD. *p < 0.05 versus Taxol® as a control.
Figure 8. Hemolytic activity of Taxol®, PTX-VE/VE/VE2-PEG2000/water NES, PTX-S-S-VE/VE/VE2-
PEG2000/water NES, and Abraxane® at 37 °C for 1 h (data are expressed as the mean ± SD, n = 3 mice 
for each measurement) (p < 0.05 [*] and p < 0.01 [**]). 
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under nitrogen atmosphere for 7 h. The resulting mixture was filtered to remove N, N-dicyclohexylurea 
(DCU) and the filtrate was dried under vacuum. The residue was purified using silica gel column chro-
matography, eluting with a chloroform-methanol solution with gradually increasing methanol content. 
The eluting solvent was removed under vacuum to give 95.9 mg of PTX-VE conjugate with the total yield 
of 60%. The purity was 99.2%, analyzed by the HPLC method.
Synthesis of PTX-SA. A solution of PTX (200.0 mg, 0.234 mmol), succinic anhydride (46.9 mg, 
0.468 mmol), a catalytic amount of DMAP, and DCM (5 mL) was stirred for 3 h at room temperature. The 
product was purified using silica gel column chromatography, eluting with a solution of chloroform and 
methanol (200:1, V/V) to obtain the target compound PTX-SA as white solid (145.0 mg, yield: 65.0%). 
The purity was 98.8%, analyzed by the HPLC method.
Synthesis of PTX-SEE. Monomethyl succinate (34.0 mg, 0.257 mmol) and dichloromethane (5 mL) were 
stirred in an ice water bath. DCC (53 mg, 0.257 mmol) and a catalytic amount of DMAP were added. 
The solution turned to suspension. After 5 min, PTX (200.0 mg, 0.234 mmol) was added. After 2 h, the 
suspension was filtered to remove DCU and then purified by silica gel column chromatography. The 
elution solution was chloroform and methanol (200:1, V/V) and the target compound was obtained as a 
white solid (110 mg, yield: 44.5%). The purity was 99.0%, analyzed by the HPLC method.
Synthesis of PTX-S-S-VE. A solution of dithiodiglycolic acid (2 g, 11.0 mmol) and anhydrous acetic 
anhydride (30 mL) was stirred at 30 °C under nitrogen atmosphere for 2 h. Acetic anhydride was removed 
at room temperature under high vacuum with the addition of toluene three times. The residue was 
added to a mixed solution of dichloromethane (20 mL), VE (1.0 g, 2.3 mmol) and a catalytic amount 
of DMAP, and stirred for 5 min at room temperature. The product was purified by silica gel column 
chromatography, eluting with a solution of hexane, ethyl acetate and acetic acid. The eluting solvent was 
removed under vacuum to give 0.757 g of acid VE-S-S-COOH with a yield of 55.3%. The acid (0.5 g, 
0.84 mmol) and dichloromethane (10 mL) were stirred in an ice water bath. DCC (0.198 g, 1.0 mmol) and 
DMAP (13.8 mg, 0.01 mmol) were added. The solution changed to a suspension. After 5 min, PTX (0.72 g, 
0.84 mmol) was added and the mixture was stirred for a further 2 h. After filtration to remove DCU, the 
solution was purified by silica gel column chromatography, eluting with a solution of chloroform and 
methanol (200:1) to obtain the target compound PTX-S-S-VE as white solid (0.814 g, yield: 67.7% ). The 
purity was 99.4%, analyzed by the HPLC method.
HPLC analysis. The HPLC system was equipped with a Waters 2487 Dual λ Absorption Detector 
and a Waters 600 pump (Waters Corporation, Milford, US). The separation was carried out on an ODS 
HYPERSIL (3 μ m, 2.1 mm × 100 mm) column (Thermo Scientific, USA) at a flow rate of 0.5 mL/min. 
Compound concentration was determined at a ultraviolet wavelength of 228 nm and the injection volume 
was 20 μ L. Gradient elution was applied with a mobile phase of acetonitrile (ACN) and water. The initial 
mobile phase composition was 40% ACN from 0–36 min, and a linear gradient was applied to reach a 
composition of 100% ACN after a further 1 min. This was maintained for 30 min and then returned to 
initial conditions within a further 1 min and equilibrated for 9 min. Total run time was 77 min.
To analyze the hydrolysis of the prodrugs (PTX-VE and PTX-S-S-VE), the initial mobile phase com-
position (40% ACN) was maintained from 0–12 min, then a linear gradient was applied to reach a com-
position of 100% ACN after a further 1 min. This was maintained for 23 min and then returned to initial 
conditions within a further 1 min.
Hydrolysis. Hydrolytic studies were carried out at 37 °C in pH 7.4 PBS containing 7% DMSO and 
0.1% Tween 80. The prodrugs (PTX-SA, PTX-SEE, PTX-VE, PTX-Br2-C16 and PTX-S-S-VE), equivalent 
to 11.7 μ M of PTX, were added to 100 mL of the medium and placed in a shaking table at a rotating rate 
of 100 rpm/min. At predetermined time intervals (4, 8, 24 and 48 h), 1 mL of the samples were drawn 
from the medium and filtered through acetate membranes (0.22 μ m, GE Water & Process Technologies, 
Trevose, PA). The filtrate was mixed with an equal volume of acetonitrile and analyzed using the HPLC 
method described earlier. The chromatograms were presented as Fig. S7.
Cytotoxicity. MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-car-boxymethoxyphenyl)-2-(4-sulfophenyl)-2H- 
tetrazolium, inner salt, was used to study the cytotoxicity of the prodrugs following the manufacture’s 
protocol. Generally, the KB-3-1 cells were seeded in 96 wells at a density of 1 × 104 cells per well. After 
incubation for 24 h, the cells were treated with PTX, PTX-SA, PTX-SEE, PTX-VE, or PTX-S-S-VE at 
various concentrations for 48 h. Sterile water treated wells were used as controls. After the incubation, the 
media was replaced with a mixture of fresh cell culture medium and MTS-based CellTiter 96® AQueous 
One Solution Cell Proliferation Assay Reagent (Promega Corporation, Madison, WI). The plate was then 
incubated at 37 °C for a further 2 h. Absorbance was determined at 480 nm using a plate reader. Cell via-
bility was calculated as ODtest/ODcontrol × 100%.
Preparation, characterization and storage stability study of the NES. PTX-VE, PTX-S-S-VE, 
VE, TPGS and VE2-TPGS were dissolved in chloroform. PTX-VE (0.70 μ M) (or PTX-S-S-VE [0.70 μ M]), 
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VE (20 μ M), TPGS (1.8 μ M) and VE2-TPGS (0.34 μ M) were added to an Eppendorf Safe Lock TubeTM 
(1.5 mL) (Next Advance Inc., Averill Park, NY) and the chloroform removed under nitrogen flow and 
further by vacuum pumping. Water (600 μ L) was then added. The mixture was probe sonicated for about 
1 min, and the initial NES were mixed with 0.5 g of beads (one third × 1.0 mm in diameter and two 
thirds × 0.5 mm in diameter). The NES were placed in a BBY24M Bullet Blender Storm (Next Advance 
Inc., Averill Park, NY) for homogenization.
The particle size and zeta potential of the NES were determined using a Malvern ZetaSizer® Nano 
ZS (Westborough, MA) three times. In addition, the morphology was observed with a JEOL 100CX II 
TEM (Tokyo, Japan).
The PTX-S-S-VE/VE/VE2-PEG2000/water NES was stored at 25 °C for 12 months. At predetermined 
time intervals, samples were withdrawn and evaluated, including the physical appearance, particle size, 
polydispersity index (PDI), and encapsulation efficiency (EE). These studies were performed in triplicate 
and data were expressed as mean ± SD.
Animal studies. All animal research work was approved by the University of North Carolina at 
Chapel Hill’s Institutional Animal Care and Use Committee and were performed in accordance with 
relevant guidelines and regulation.
Biodistribution. Balb/C nude mice (6–8 weeks) were used to evaluate the in vivo biodistribution of 
the formulations. The xenograft models were established by subcutaneous injection of KB-3-1 (5 × 106) 
cells into the right flanks of the mice. Fifteen mice were randomly divided into three groups (n = 5 for 
each group) to receive Taxol®, PTX-VE/VE/VE2-PEG2000/water or PTX-S-S-VE/VE/VE2-PEG2000/water 
NES, respectively. The formulations were administered intravenously via the tail vein at a single dose of 
20 mg/kg PTX equivalent. After 4 h, the mice were sacrificed, and the plasma, heart, liver, spleen, lungs, 
kidney, and tumor were collected. The tissues were homogenized with 300 μ L of HPLC initial mobile 
phase (ACN:water = 40:60, w/w) using the BBY24M Bullet Blender Storm. The supernatant was obtained 
by centrifuging the tubes. The PTX and/or prodrugs (PTX-VE and PTX-S-S-VE) were extracted using 
methyl tert-butyl ether, with PTX-SEE (11.7 μ M) as internal standard. The organic phase was transferred 
to a glass tube and evaporated under nitrogen flow. The residues were redispersed using the initial mobile 
phase 40:60 (ACN:water, v/v). Analysis was carried out by the HPLC method described earlier.
In vivo anticancer effect. The KB-3-1 tumor bearing nude mice were randomly divided into four 
groups (n = 5 for each group) to intravenously receive PTX equivalent doses (5 mg/kg) of Taxol® , 
PTX-VE NES, PTX-S-S-VE NES or physiological saline. The treatments were started on the third day 
after inoculation, and tumor sizes and body weights were monitored every second day. Tumor volume 
was calculated as V = 0.5× (L × W2), where V represents tumor volume, L the larger perpendicular diam-
eter and W the smaller one.
Histopathological examination. The histopathological examinations were conducted on the organs 
of the sacrificed mice. The tissues, including heart, liver, spleen, lung, and kidney, were collected, rinsed 
with normal saline, fixed in 10% formalin, and then stained with hematoxylin and eosin. Finally, the 
sections were observed under a microscope for histopathological evaluations.
Measurement of serum level. Ten CD1 mice were used for the analysis of serum biochemistry. The 
mice were randomly divided into two groups (n = 5 for each group) to receive Taxol® and PTX-S-S-VE/
VE/VE2-PEG2000/water NES, respectively. The blood samples were collected by enucleating the eyeball 
after mice received 5 times 10 mg/kg PTX equivalent every second day, and the serum was obtained 
by coagulating and then centrifuging. Subsequently, the serum samples were analyzed using an AU640 
blood biochemical analyzer (Olympus Co., Tokyo, Japan). The serum biochemistry analysis involved 
the determination of aspartate aminotransferase (AST), alanine transaminase (ALT), and blood urea 
nitrogen (BUN).
Hemolysis. To test the potential toxicity of the NES, hemolysis was evaluated. Blank blood was 
obtained by orbital collection from the CD1 mice. Erythrocytes were immediately obtained by centri-
fuging the whole blood and washing twice with PBS (pH 7.4) to remove plasma and serum. The isolated 
erythrocytes (3 × 1010 cells) were resuspended and incubated with the formulations at various concentra-
tions at 37 °C for 1 h. The samples were then centrifuged for 10 min at 16000 g, and 100 μ L supernatants 
were diluted with an equal volume of PBS and measured for optical density (OD) at 570 nm. A complete 
hemolytic sample, which was used as a control, was prepared by sonicating blood for 3 min. The percent-
age of hemolysis was calculated as (ODtest – ODformulation) /ODcontrol × 100%36.
Statistical analysis. All data were expressed as mean ± SD and were analyzed statistically using a 
one-way analysis of variance (ANOVA) or a two tailed Student’s t-test. The differences were considered 
statistically significant if the p value was less than 0.05 (p < 0.05).
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Conclusion
In this study, by giving a comparison of hydrolytic release and cytotoxicity for the three conjugates 
(PTX-VE, PTX-SA, and PTX-SEE), we have found that polarity and steric hindrance are two major 
factors influencing anticancer activity. Thus, we have designed a programmably hydrolyzable PTX prod-
rug, PTX-S-S-VE, which undergoes two subsequent hydrolysis steps and releases active drug. Like the 
previous PTX-VE, PTX-S-S-VE can also be encapsulated in VE/VE2-PEG2000/water NES for intrave-
nous administration. The in vivo distribution for the two NES formulations varied a lot. In nude mice, 
PTX-S-S-VE/VE/VE2-PEG2000/water NES had better anticancer activity against KB-3-1 cell line tum-
ors than PTX-VE/VE/VE2-PEG2000/water NES. Both the hemolysis activity was reduced compared with 
Taxol®. In conclusion, the programmably hydrolyzable PTX prodrug that we have produced demon-
strates a bright future for controlling drug release in the treatment of cancer.
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